Jean-Philippe Stéphan

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index3.9kcitations119works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(22), Monoclonal and Polyclonal Antibodies Research(20), Growth Hormone and Insulin-like Growth Factors(16), Angiogenesis and VEGF in Cancer(15), Glutathione Transferases and Polymorphisms(15)

Publications119 total

Supplementary Fig. S2 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Supplementary Fig. S1 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Supplementary Fig. S3 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Supplementary Figure 4 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Supplementary Figure 2 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Supplementary Fig. S2 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Data from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Supplementary Figure 1 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Supplementary Figure 3 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Supplementary Figure 6 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Supplementary Figure 1 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Supplementary Figure 5 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Data from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Supplementary Fig. S3 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Supplementary Fig. S1 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Supplementary Figure 5 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Supplementary Table S2 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
Supplementary Figure 3 from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Data from Identification and Analysis of <i>In Vivo</i> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
2023Open Access
Supplementary Table S1 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Sarajane Ross(9), Suzie J. Scales(9), Benjamin Haley(8), Zora Modrušan(8), Pamela Chan(7), Avi Ashkenazi(7), Bernard Jégou(7), Klára Tótpál(6), Janet Tien(6), Hartmut Koeppen(6), Richard Vandlen(6), Siao Ping Tsai(5), Gail D. Lewis Phillips(5), Wesley Chang(5), Gladys S. Ingle(5), Allen Ebens(5), Jiping Zha(5), Christine Tan(5), Gretchen Frantz(4), Jeff Settleman(4)